Drug interaction alert override rates in the Meaningful Use era: no evidence of progress.
Interruptive drug interaction alerts may reduce adverse drug events and are required for Stage I Meaningful Use attestation. For the last decade override rates have been very high. Despite their widespread use in commercial EHR systems, previously described interventions to improve alert frequency and acceptance have not been well studied.
Author(s): Bryant, A D, Fletcher, G S, Payne, T H
DOI: 10.4338/ACI-2013-12-RA-0103